Syndax Pharmaceuticals Inc. (SNDX)
Nasdaq · Pharmaceutical Preparations · Manufacturing · CIK 1395937 · fiscal year ends in Dec
Closing price $14.13 on 29 Oct 2026; 52-week range $12.91 to $25.15.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $252.0M
- Revenue growth
- 222.3%
- Net income, last twelve months
- -$220.8M
- Earnings per share
- -$2.51
- Operating margin
- -77.1%
- Net margin
- -87.6%
- Return on equity
- -1462.1%
- Market value
- $1.3B
- Cash
- $336.5M
- Debt
- $244.1M
- Debt to equity
- 16.17
- Shares outstanding
- 89.2M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $172.4M | -$273.1M | -$285.4M | -$3.29 | -$323.2M | 10-K filed 26 Feb 2026 |
| FY2024 | 31 Dec 2024 | $23.7M | -$339.7M | -$318.8M | -$3.72 | -$274.9M | 10-K filed 3 Mar 2025 |
| FY2023 | 31 Dec 2023 | $0 | -$230.0M | -$209.4M | -$2.98 | -$160.6M | 10-K filed 27 Feb 2024 |
| FY2022 | 31 Dec 2022 | $0 | -$151.8M | -$149.3M | -$2.46 | -$133.7M | 10-K filed 27 Feb 2024 |
| FY2021 | 31 Dec 2021 | $139.7M | $26.2M | $24.9M | $0.46 | $29.0M | 10-K filed 1 Mar 2022 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $72.8M | -$49.4M | -$0.55 |
| Q1 FY2026 | 31 Mar 2026 | $64.9M | -$42.7M | -$0.48 |
| Q4 FY2025 | 31 Dec 2025 | $68.5M | -$68.0M | -$0.78 |
| Q3 FY2025 | 30 Sep 2025 | $45.9M | -$60.7M | -$0.70 |
| Q2 FY2025 | 30 Jun 2025 | $38.0M | -$71.8M | -$0.83 |
| Q1 FY2025 | 31 Mar 2025 | $20.0M | -$84.8M | -$0.98 |
| Q4 FY2024 | 31 Dec 2024 | $7.7M | -$94.2M | -$1.10 |
| Q3 FY2024 | 30 Sep 2024 | $12.5M | -$84.1M | -$0.98 |
Revenue by segment
As the company reports it in the segment note of its annual report.
By product, FY2025
| Segment | Revenue | Share |
|---|---|---|
| Net product revenue | $124.8M | 72.4% |
| Collaboration revenue | $42.4M | 24.6% |
| Milestone revenue | $5.1M | 3.0% |
Company events
The newest 8-K filings of 114 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 4 Aug 2026 | 8-K | Results | 2.02, 9.01 |
| 14 Jul 2026 | 8-K | Other events | 8.01, 9.01 |
| 10 Jun 2026 | 8-K | Material agreement, New debt, Share sale | 1.01, 2.03, 3.02, 9.01 |
| 10 Jun 2026 | 8-K | Leadership change, Shareholder vote | 5.02, 5.07, 9.01 |
| 4 Jun 2026 | 8-K | Material agreement, New debt, Share sale, Other events | 1.01, 2.03, 3.02, 8.01, 9.01 |
| 30 Apr 2026 | 8-K | Results | 2.02, 9.01 |
| 26 Feb 2026 | 8-K | Results | 2.02, 9.01 |
| 12 Jan 2026 | 8-K | Results, Investor update | 2.02, 7.01 |
| 19 Dec 2025 | 8-K | Bylaws or fiscal year change | 5.03 |
| 3 Nov 2025 | 8-K | Results | 2.02, 9.01 |
| 24 Oct 2025 | 8-K | Other events | 8.01, 9.01 |
| 4 Aug 2025 | 8-K | Results | 2.02, 9.01 |
Every filing
The newest filings with the SEC of 264 held.
| Filed | Form | Period |
|---|---|---|
| 4 Aug 2026 | 10-Q | 30 Jun 2026 |
| 4 Aug 2026 | 8-K | 4 Aug 2026 |
| 14 Jul 2026 | 8-K | 14 Jul 2026 |
| 10 Jun 2026 | 8-K | 10 Jun 2026 |
| 10 Jun 2026 | 8-K | 10 Jun 2026 |
| 4 Jun 2026 | DEFA14A | – |
| 4 Jun 2026 | 8-K | 3 Jun 2026 |
| 30 Apr 2026 | ARS | 31 Dec 2025 |
| 30 Apr 2026 | DEFA14A | – |
| 30 Apr 2026 | DEF 14A | 30 Apr 2026 |
| 30 Apr 2026 | 10-Q | 31 Mar 2026 |
| 30 Apr 2026 | 8-K | 30 Apr 2026 |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 8 Jul 2026 | Metzger Michael A, Chief Executive Officer | Sale under a trading plan | 32,375 | $24.24 | $784.8K | 484,843 | 9 Jul 2026 |
| 12 Jun 2026 | Botwood Nicholas A.J., Head of R&D, CMO | Sale under a trading plan | 31,235 | $18.14 | $566.6K | 60,885 | 12 Jun 2026 |
| 11 Jun 2026 | Botwood Nicholas A.J., Head of R&D, CMO | Sale under a trading plan | 34,280 | $18.00 | $617.0K | 60,885 | 12 Jun 2026 |
| 1 Jun 2026 | Goldan Keith A., Chief Financial Officer | Sale outside a trading plan | 1,177 | $18.99 | $22.4K | 139,252 | 2 Jun 2026 |
| 1 Jun 2026 | Metzger Michael A, Chief Executive Officer | Sale outside a trading plan | 6,847 | $18.99 | $130.0K | 484,843 | 2 Jun 2026 |
| 9 Feb 2026 | Metzger Michael A, Chief Executive Officer | Sale outside a trading plan | 17,159 | $21.03 | $360.8K | 491,690 | 10 Feb 2026 |
| 9 Feb 2026 | Goldan Keith A., Chief Financial Officer | Sale outside a trading plan | 3,410 | $21.03 | $71.7K | 140,429 | 10 Feb 2026 |
| 6 Feb 2026 | Metzger Michael A, Chief Executive Officer | Sale outside a trading plan | 7,412 | $20.62 | $152.8K | 508,849 | 6 Feb 2026 |
| 6 Feb 2026 | Goldan Keith A., Chief Financial Officer | Sale outside a trading plan | 2,082 | $20.62 | $42.9K | 143,839 | 6 Feb 2026 |
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| Filed | Seller | Shares | Value | Planned sale |
|---|---|---|---|---|
| 29 Oct 2026 | DENNIS G PODLESAK, Director | 8,000 | $114.6K | 29 Oct 2026 |
| 8 Jul 2026 | MICHAEL METZGER, Director, Officer | 32,375 | $752.4K | 8 Jul 2026 |
| 12 Jun 2026 | Botwood Nicholas A.J., Officer | 31,235 | $566.7K | 12 Jun 2026 |
| 11 Jun 2026 | Botwood Nicholas A.J., Officer | 34,280 | $609.4K | 11 Jun 2026 |
| 1 Jun 2026 | Goldan Keith A., Officer | 1,177 | $22.4K | 1 Jun 2026 |
| 1 Jun 2026 | Metzger Michael A, Officer, Director | 6,847 | $130.0K | 1 Jun 2026 |
| 9 Feb 2026 | Goldan Keith A., Officer | 3,410 | $71.7K | 9 Feb 2026 |
| 9 Feb 2026 | Metzger Michael A, Officer, Director | 17,159 | $360.8K | 9 Feb 2026 |
| 6 Feb 2026 | Goldan Keith A., Officer | 2,082 | $42.9K | 6 Feb 2026 |
| 6 Feb 2026 | Metzger Michael A, Officer, Director | 7,412 | $152.8K | 6 Feb 2026 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 7 Aug 2026 | STATE STREET CORPORATION | 13G | 6.4% | 5.7M |
| 15 May 2026 | Point72 Asset Management, L.P. | 13G amended | 2.3% | 2.0M |
| 30 Apr 2026 | Vanguard Capital Management | 13G | 5.05% | 4.5M |
| 27 Mar 2026 | The Vanguard Group | 13G amended | 0% | 0 |
| 9 Feb 2026 | STATE STREET CORPORATION | 13G | 5.3% | 4.6M |
| 30 Jan 2026 | The Vanguard Group | 13G amended | 7.16% | 6.2M |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 18.0M | -1.28% | 7.64 |
| 30 Sep 2026 | 18.2M | -11.74% | 8.47 |
| 15 Sep 2026 | 20.7M | -4.71% | 14.73 |
| 31 Aug 2026 | 21.7M | -5.33% | 19.65 |
| 14 Aug 2026 | 22.9M | +1.05% | 15.03 |
| 31 Jul 2026 | 22.7M | +8.88% | 18.58 |
| 15 Jul 2026 | 20.8M | -4.57% | 9.83 |
| 30 Jun 2026 | 21.8M | +9.86% | 8.56 |
Funds that hold it
From each fund's latest Form 13F.
281 funds held it at 30 Jun 2026: 127 added and 75 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| BlackRock, Inc. | 9,020,006 | $197.2M | +765,580 |
| Kynam Capital Management, LP | 8,050,959 | $176.0M | 0 |
| Goldman Sachs Group Inc. | 5,861,265 | $128.1M | +864,478 |
| State Street Corp. | 5,658,424 | $123.7M | +1,228,348 |
| Bank of America Corp. | 4,045,094 | $88.4M | -204,742 |
| Vanguard Capital Management LLC | 3,927,892 | $85.9M | +105,313 |
| Deerfield Management Company, L.P. | 3,779,900 | $82.6M | 0 |
| Eversept Partners, LP | 2,798,210 | $61.2M | -87,412 |
| Geode Capital Management, LLC | 2,584,136 | $56.5M | +427,078 |
| Hood River Capital Management LLC | 2,564,279 | $56.1M | +209,994 |
Peers
Companies in the same industry.
- Eli Lilly & Co. (LLY): revenue $86.5B, market value $1.29T
- Johnson & Johnson (JNJ): revenue $99.3B, market value $662.4B
- AbbVie Inc. (ABBV): revenue $64.4B, market value $513.9B
- Merck & Co., Inc. (MRK): revenue $66.6B, market value $361.0B
- Novartis AG (NVS): revenue $54.5B, market value $307.3B
- AstraZeneca PLC (AZN): revenue $58.7B, market value $270.6B
- Abbott Laboratories (ABT): revenue $46.6B, market value $180.9B
- Novo Nordisk A/S (NVO): revenue $46.8B, market value $174.8B
- Pfizer Inc. (PFE): revenue $63.7B, market value $170.7B
- Vertex Pharmaceuticals Inc. (VRTX): revenue $12.6B, market value $136.8B